Viridian Narrows Q3 Loss to $34.6M on Soaring License Revenue
Ticker: VRDN · Form: 10-Q · Filed: Nov 5, 2025 · CIK: 1590750
Sentiment: mixed
Topics: Biotechnology, Clinical Trials, Drug Development, Net Loss, License Revenue, R&D Expenses, Cash Position, Regulatory Approval
Related Tickers: VRDN
TL;DR
**VRDN's Q3 loss narrowed significantly due to a massive license revenue boost, making it a speculative buy for risk-tolerant investors betting on pipeline success.**
AI Summary
Viridian Therapeutics, Inc. reported a net loss of $34.599 million for the three months ended September 30, 2025, a significant improvement from the $76.689 million net loss in the same period of 2024. This improvement was primarily driven by a substantial increase in total revenue, which surged from $86 thousand in Q3 2024 to $70.570 million in Q3 2025, largely due to $70.000 million in license revenue. However, research and development expenses also increased to $86.261 million in Q3 2025 from $69.158 million in Q3 2024, reflecting ongoing clinical trial activities for product candidates like VRDN-003 and VRDN-008. The company's cash and cash equivalents increased to $169.647 million as of September 30, 2025, up from $99.594 million at December 31, 2024, while short-term investments decreased from $617.990 million to $321.254 million. The accumulated deficit expanded to $1.218 billion by September 30, 2025, from $995.857 million at December 31, 2024, indicating continued operational losses. Strategic outlook includes anticipated IND submission for VRDN-008 by end of 2025 and BLA/MAA filings for veligrotug in Q1 2026.
Why It Matters
Viridian's ability to secure $70 million in license revenue is a critical validation of its pipeline, potentially signaling external confidence in its drug candidates like veligrotug and VRDN-003. For investors, this revenue infusion, despite increased R&D, suggests a potential pathway to commercialization and reduced cash burn, which is vital for a clinical-stage biotech. Employees and customers could see enhanced job security and future access to innovative treatments, respectively, if these candidates gain approval. In the competitive biotech landscape, this revenue stream could strengthen Viridian's position against rivals developing similar therapies, allowing for continued investment in its promising pipeline.
Risk Assessment
Risk Level: high — Viridian Therapeutics continues to incur significant losses, with an accumulated deficit of $1.218 billion as of September 30, 2025, and a net loss of $222.246 million for the nine months ended September 30, 2025. The company is heavily dependent on the success of product candidates like veligrotug and VRDN-003, which are still in clinical development and face lengthy, unpredictable regulatory approval processes, as highlighted in the 'Summary of the Material Risks'.
Analyst Insight
Investors should closely monitor the progress of veligrotug's BLA/MAA filings in Q1 2026 and the IND submission for VRDN-008 by year-end 2025. Given the high-risk, high-reward nature of clinical-stage biotechs, consider a small, speculative position if you believe in the long-term potential of their pipeline, but be prepared for volatility.
Financial Highlights
- debt To Equity
- 0.15
- revenue
- $70.570M
- operating Margin
- -56.7%
- total Assets
- $577.138M
- total Debt
- $20.890M
- net Income
- $-34.599M
- eps
- $-0.34
- gross Margin
- N/A
- cash Position
- $169.647M
- revenue Growth
- +81,925%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| License revenue | $70,000,000 | N/A |
| Collaboration revenue - related party | $717,000 | +212% |
Key Numbers
- $70.570M — Total Revenue (Increased from $86K in Q3 2024 to $70.570M in Q3 2025, primarily due to license revenue.)
- $34.599M — Net Loss (Q3 2025) (Improved from a net loss of $76.689M in Q3 2024.)
- $222.246M — Net Loss (YTD Sep 2025) (Increased from $190.224M for the nine months ended September 30, 2024.)
- $86.261M — Research and Development Expenses (Q3 2025) (Increased from $69.158M in Q3 2024, reflecting ongoing clinical activities.)
- $169.647M — Cash and Cash Equivalents (Increased from $99.594M at December 31, 2024.)
- $321.254M — Short-term Investments (Decreased from $617.990M at December 31, 2024.)
- $1.218B — Accumulated Deficit (Expanded from $995.857M at December 31, 2024, indicating continued losses.)
- 95,442,008 — Common Shares Outstanding (As of October 31, 2025, indicating potential dilution.)
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — registrant of the 10-Q filing
- VRDN-003 (company) — product candidate in clinical development
- VRDN-008 (company) — product candidate with anticipated IND submission
- veligrotug (company) — product candidate with anticipated BLA/MAA filings
- U.S. Food and Drug Administration (regulator) — regulatory authority for drug approvals
- European Medicines Agency (regulator) — regulatory authority for drug approvals in Europe
- Nasdaq Stock Market LLC (company) — exchange where VRDN common stock is registered
- Bloomberg (company) — financial news organization
- SEC (regulator) — Securities and Exchange Commission
FAQ
What was Viridian Therapeutics' net loss for the third quarter of 2025?
Viridian Therapeutics reported a net loss of $34.599 million for the three months ended September 30, 2025, which is an improvement compared to the $76.689 million net loss in the same period of 2024.
How did Viridian Therapeutics' revenue change in Q3 2025?
Total revenue for Viridian Therapeutics increased significantly to $70.570 million for the three months ended September 30, 2025, up from $86 thousand in the prior year's quarter. This surge was primarily driven by $70.000 million in license revenue.
What are Viridian Therapeutics' key product candidates and their development status?
Viridian Therapeutics' key product candidates include veligrotug, for which a Biologics License Application (BLA) to the FDA and a Marketing Authorization Application (MAA) to the EMA are anticipated in Q1 2026, and VRDN-008, for which an Investigational New Drug (IND) Application is expected by the end of 2025.
What were Viridian Therapeutics' research and development expenses in Q3 2025?
Research and development expenses for Viridian Therapeutics were $86.261 million for the three months ended September 30, 2025, an increase from $69.158 million in the same period of 2024, reflecting ongoing clinical trial investments.
What is Viridian Therapeutics' cash position as of September 30, 2025?
As of September 30, 2025, Viridian Therapeutics had cash and cash equivalents of $169.647 million. This is an increase from $99.594 million reported at December 31, 2024.
What are the main risks for investors in Viridian Therapeutics?
Key risks for investors include the company's history of significant losses, an accumulated deficit of $1.218 billion, and heavy dependence on the successful, timely, and costly clinical development and regulatory approval of its product candidates, which is inherently unpredictable.
How many shares of common stock did Viridian Therapeutics have outstanding?
As of October 31, 2025, Viridian Therapeutics had 95,442,008 shares of common stock outstanding. This figure is important for understanding per-share metrics and potential dilution.
What is the strategic outlook for Viridian Therapeutics regarding regulatory filings?
Viridian Therapeutics anticipates submitting an Investigational New Drug Application (IND) for VRDN-008 by the end of 2025. Additionally, the company expects to file a Biologics License Application (BLA) with the FDA and a Marketing Authorization Application (MAA) with the EMA for veligrotug in the first quarter of 2026.
Did Viridian Therapeutics experience any changes in its short-term investments?
Yes, Viridian Therapeutics' short-term investments decreased significantly to $321.254 million as of September 30, 2025, down from $617.990 million at December 31, 2024.
What is the significance of the $70 million license revenue for Viridian Therapeutics?
The $70 million in license revenue is significant as it represents a new, substantial income stream for Viridian Therapeutics, contributing to a narrowed net loss in Q3 2025 and potentially validating the value and progress of its intellectual property and pipeline to external partners.
Risk Factors
- Continued Accumulated Deficit [high — financial]: The company's accumulated deficit increased to $1.218 billion as of September 30, 2025, from $995.857 million at December 31, 2024. This indicates ongoing operational losses and a substantial historical negative net income.
- High R&D Expenses [high — operational]: Research and development expenses rose to $249.721 million for the nine months ended September 30, 2025, up from $166.294 million in the prior year period. This significant increase reflects substantial investment in clinical trial activities for product candidates.
- Dependence on Future Financing [medium — financial]: Despite an increase in cash and cash equivalents to $169.647 million, the company continues to incur significant net losses. Future funding will likely be required to support ongoing operations and development, potentially through equity or debt financing.
- Product Development and Approval Risks [high — regulatory]: The company is advancing product candidates like VRDN-008 and veligrotug. Delays in IND submissions (VRDN-008 by end of 2025) or BLA/MAA filings (veligrotug in Q1 2026), or failure to obtain regulatory approval, pose significant risks to future revenue and viability.
- Decrease in Short-Term Investments [medium — financial]: Short-term investments decreased significantly from $617.990 million at December 31, 2024, to $321.254 million as of September 30, 2025. This could indicate deployment of capital or a strategic shift in asset allocation.
Industry Context
Viridian Therapeutics operates in the highly competitive biotechnology sector, focusing on developing novel therapeutics. The industry is characterized by significant R&D investment, long development cycles, and high regulatory hurdles. Success often hinges on scientific innovation, successful clinical trials, and securing substantial funding to navigate these challenges.
Regulatory Implications
The company faces significant regulatory risks associated with its product development pipeline. Successful IND submissions for VRDN-008 by end of 2025 and BLA/MAA filings for veligrotug in Q1 2026 are critical milestones. Any delays or failures in these regulatory processes could severely impact the company's future prospects and financial health.
What Investors Should Do
- Monitor R&D progress and regulatory milestones
- Assess the sustainability of revenue growth
- Evaluate cash burn rate and future funding needs
- Analyze the impact of the accumulated deficit
Key Dates
- 2025-09-30: End of Q3 2025 — Reported total revenue of $70.570 million and a net loss of $34.599 million. Cash and cash equivalents stood at $169.647 million.
- 2025-12-31: Anticipated IND submission for VRDN-008 — Key regulatory milestone for a promising product candidate, crucial for advancing development.
- 2026-03-31: Anticipated BLA/MAA filings for veligrotug — Critical step towards potential market approval for a key therapeutic, impacting future revenue streams.
- 2024-12-31: End of Fiscal Year 2024 — Reported cash and cash equivalents of $99.594 million and an accumulated deficit of $995.857 million.
Glossary
- Accumulated deficit
- The cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total losses that have not been offset by profits. (Indicates the company's historical unprofitability, with the deficit expanding to $1.218 billion.)
- IND submission
- Investigational New Drug application. A submission to the FDA to request permission to start clinical trials in humans for a new drug. (The anticipated submission for VRDN-008 by end of 2025 is a critical step for its development.)
- BLA/MAA filings
- Biologics License Application (BLA) in the US and Marketing Authorisation Application (MAA) in Europe. These are applications submitted to regulatory authorities to seek approval to market a biologic drug. (The planned filings for veligrotug in Q1 2026 are crucial for potential commercialization.)
- Unbilled revenue
- Revenue that has been earned by the company but has not yet been invoiced to the customer. Often arises from long-term contracts or services rendered but not yet billed. (A $70,000,000 unbilled revenue line item appears on the balance sheet as of September 30, 2025, likely related to the license revenue.)
- Weighted-average common shares outstanding
- The average number of common shares outstanding during a reporting period, adjusted for the timing of share issuances or repurchases. Used to calculate earnings per share. (Essential for calculating EPS, which was $-0.34 for Q3 2025.)
Year-Over-Year Comparison
Viridian Therapeutics shows a dramatic increase in total revenue for Q3 2025, surging to $70.570 million from just $86 thousand in the prior year, primarily due to license revenue. This revenue growth has helped narrow the net loss for the quarter to $34.599 million from $76.689 million year-over-year. However, operating expenses, particularly R&D, have also escalated significantly, contributing to a widening net loss on a year-to-date basis. The company's cash position has improved, but short-term investments have decreased substantially.
Filing Stats: 4,690 words · 19 min read · ~16 pages · Grade level 20 · Accepted 2025-11-05 07:57:29
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share VRDN The Nasdaq Sto
Filing Documents
- vrdn-20250930.htm (10-Q) — 1665KB
- ex101kissei_viridianxcolla.htm (EX-10.1) — 818KB
- ex1022025-09x06bixwatchfac.htm (EX-10.2) — 100KB
- ex311_2025-09.htm (EX-31.1) — 11KB
- ex312_2025-09.htm (EX-31.2) — 12KB
- ex321_2025-09.htm (EX-32.1) — 9KB
- exa-17firstfloorriverlevela.jpg (GRAPHIC) — 51KB
- exa-18suite107a.jpg (GRAPHIC) — 64KB
- image_1a.jpg (GRAPHIC) — 158KB
- image_2a.jpg (GRAPHIC) — 150KB
- image_4a.jpg (GRAPHIC) — 136KB
- 0001590750-25-000020.txt ( ) — 10061KB
- vrdn-20250930.xsd (EX-101.SCH) — 54KB
- vrdn-20250930_cal.xml (EX-101.CAL) — 60KB
- vrdn-20250930_def.xml (EX-101.DEF) — 377KB
- vrdn-20250930_lab.xml (EX-101.LAB) — 708KB
- vrdn-20250930_pre.xml (EX-101.PRE) — 530KB
- vrdn-20250930_htm.xml (XML) — 1037KB
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION
Financial Statements (Unaudited)
Item 1. Financial Statements (Unaudited) 6 Condensed Consolidated Balance Sheets 6 Condensed Consolidated Statements of Operations and Comprehensive Loss 7 Condensed Consolidated Statements of Changes in Stockholders' Equity 8 Condensed Consolidated Statements of Cash Flows 9 Notes to Unaudited Condensed Consolidated Financial Statements 11
Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 36
Quantitative and Qualitative Disclosures about Market Risk
Item 3. Quantitative and Qualitative Disclosures about Market Risk 47
Controls and Procedures
Item 4. Controls and Procedures 47
OTHER INFORMATION
PART II. OTHER INFORMATION
Legal Proceedings
Item 1. Legal Proceedings 47
Risk Factors
Item 1A. Risk Factors 48
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 88
Defaults Upon Senior Securities
Item 3. Defaults Upon Senior Securities 88
Mine Safety Disclosures
Item 4. Mine Safety Disclosures 88
Other Information
Item 5. Other Information 88
Exhibits
Item 6. Exhibits 88 2 Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q ("Quarterly Report") contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward looking statements contained in this Quarterly Report include, but are not limited to, statements about: the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other results; the potential utility, efficacy, potency, safety, clinical benefits, half-life, clinical response, convenience and number of indications of our product candidates, including our expectation that VRDN-003 will demonstrate a similar clinical response as veligrotug; the timing and focus of our ongoing and future nonclinical studies and clinical trials and the timing of reporting data from those studies and trials, including that we anticipate submitting an Investigational New Drug Application ("IND") for VRDN-008 by the end of 2025; supply chain disruptions, enrollment in clinical trials involving our product candidates or other delays in such trials; our plans relating to commercializing our product candidates, including our plans to commercialize products candidates as combination products, if approved, including the geographic areas of focus and sales strategy; potential market sizes and market opportunities, including the rate and degree of market acceptance and clinical utility for our product
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION
FINANCIAL STATEMENTS
ITEM 1. FINANCIAL STATEMENTS VIRIDIAN THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data) (Unaudited) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 169,647 $ 99,594 Short-term investments 321,254 617,990 Unbilled revenue 70,000 — Prepaid expenses and other current assets 11,012 20,877 Total current assets 571,913 738,461 Property and equipment, net 1,125 1,236 Operating lease right-of-use asset 2,582 2,205 Other assets 1,518 501 Total assets $ 577,138 $ 742,403 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 10,063 $ 2,143 Accrued liabilities 40,633 45,731 Total current liabilities 50,696 47,874 Long-term debt 20,890 20,582 Other liabilities 2,582 2,308 Total liabilities 74,168 70,764 Commitments and contingencies (Note 7) Stockholders' equity: Preferred stock, series A non-voting convertible preferred stock, $ 0.01 par value; 435,000 shares authorized; 134,864 shares issued and outstanding as of September 30, 2025 and December 31, 2024 61,188 61,188 Preferred stock, series B non-voting convertible preferred stock, $ 0.01 par value; 500,000 shares authorized; 145,160 shares issued and outstanding as of September 30, 2025 and December 31, 2024 127,697 127,697 Common stock, $ 0.01 par value; 200,000,000 shares authorized; 82,229,158 and 80,994,046 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 822 810 Additional paid-in capital 1,531,003 1,477,811 Accumulated other comprehensive income (loss) 363 ( 10 ) Accumulated deficit ( 1,218,103 ) ( 995,857 ) Total stockholders' equity 502,970 671,639 Total liabilities and stockholders' equity $ 577,138 $ 742,403 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 6 Table of Contents VIRIDIAN THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS